Early Renal Remission Is Associated with Increased Likelihood of Subsequent Remission in Lupus Nephritis: Single-Centre Observational Study in Australia
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26199634 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Shiori Nakagawa und 5 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Research Group, Centre for Inflammatory Diseases, School of Clinical Sciences, Monash University, Clayton, VIC 3168, Australia. Hauptthemen laut MEDLINE: Lupus Nephritis, Kidney. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Reliable clinical markers for predicting sustained renal remission remain poorly understood in patients with lupus nephritis (LN). We investigated whether achieving complete renal remission (CRR) within 6 months of induction therapy, compared to within 12 months, was associated with a higher likelihood of attaining CRR at 24 months. We conducted a retrospective observational study of biopsy-proven patients with class III or IV ± V LN treated at a lupus clinic in Australia. CRR was defined as a urine protein: creatinine ratio (UPCR) of 10% from baseline. CRR responders at 6, 12, and 24 months were determined. Associations between 6- and 12-month CRR status and 24-month CRR were examined using logistic regression. In total, 60 patients were included; 49 (82%) were female, with a median age of 27 years (IQR: 19, 39) at LN diagnosis. CRR was attained at 6, 12, and 24 months by 23 (40%), 26 (47%), and 24 (44%) of patients, respectively. Both 6- and 12-month CRR attainment were significantly associated with an increased likelihood of CRR achievement at 24 months (adjusted odds ratios 11.23 (95% CI 2.53, 49.88) and 11.39 (95% CI 2.41, 53.80), respectively). Achieving CRR at 6 and 12 months was a strong independent predictor for attaining subsequent renal remission.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Rheumatology Research Group, Centre for Inflammatory Diseases, School of Clinical Sciences, Monash University, Clayton, VIC 3168, Australia.
- The George Institute for Global Health, University of New South Wales, Sydney, NSW 2052, Australia.
- Department of Nephrology and Transplantation, Guy's and St Thomas' NHS Foundation Trust, London SE1 7EH, UK.
- Department of Nephrology, Monash Health, Clayton, VIC 3168, Australia.
- Department of Rheumatology, Monash Health, Clayton, VIC 3168, Australia.
ORCID-Profile: Shiori Nakagawa, Emily K Yeung, Eric F Morand
Zitieren
APA
Nakagawa, S., Yeung, E. K., Hoi, A., Morand, E. F., Kent, J. R., & Kandane-Rathnayake, R. (2025). Early Renal Remission Is Associated with Increased Likelihood of Subsequent Remission in Lupus Nephritis: Single-Centre Observational Study in Australia. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26199634
Vancouver
Nakagawa S, Yeung EK, Hoi A, Morand EF, Kent JR, Kandane-Rathnayake R. Early Renal Remission Is Associated with Increased Likelihood of Subsequent Remission in Lupus Nephritis: Single-Centre Observational Study in Australia. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26199634
BibTeX
@article{Nakagawa2025,
author = {Nakagawa, Shiori and Yeung, Emily K and Hoi, Alberta and Morand, Eric F and Kent, Joanna R and Kandane-Rathnayake, Rangi},
title = {Early Renal Remission Is Associated with Increased Likelihood of Subsequent Remission in Lupus Nephritis: Single-Centre Observational Study in Australia},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26199634}
}
EUVIMED